IFNG and oropharynx cancer: Another clinical study of AXAL in previously untreated, surgically resectable, stage II–IV oropharyngeal cancer found increased interferon gamma (IFN-g), tumor necrosis factor alpha (TNF-a), and tumor-infiltrating T cells after receiving the vaccine before and after surgery [48] (NCT02002182).